DDInter1158 DDInter1822
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Aminoglycosides, many of which are derived directly from _Streptomyces_ spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic _Pseudomonas aeruginosa_ infections in cystic fibrosis patients, as _P. aeruginosa_ is notoriously inherently resistant to many antibiotics.[A232294, A232299, L32739] However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria.[L32744, L32749] Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.[A232294, A232349, L32739, L32749] Tobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).[L32739, L32744, L32749]
Mesalazine {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Tobramycin
Mesalazine {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Mesalazine {u} (Compound) downregulates {v} (Gene) NME1
NME1 {u} (Gene) is downregulated by {v} (Compound) Paromomycin
Paromomycin {u} (Compound) resembles {v} (Compound) Tobramycin
Mesalazine {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Kanamycin
Kanamycin {u} (Compound) resembles {v} (Compound) Tobramycin
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} (Compound) resembles {v} (Compound) Tobramycin
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} (Compound) causes {v} (Side Effect) Tubulointerstitial nephritis
Tubulointerstitial nephritis {u} (Side Effect) is caused by {v} (Compound) Tobramycin
Mesalazine {u} (Compound) resembles {v} (Compound) Salicylate-sodium
Salicylate-sodium {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Tobramycin
Mesalazine (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Tobramycin (Compound)
Mesalazine (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Kanamycin (Compound) and Kanamycin (Compound) resembles Tobramycin (Compound)
Mesalazine (Compound) downregulates NME1 (Gene) and NME1 (Gene) is downregulated by Paromomycin (Compound) and Paromomycin (Compound) resembles Tobramycin (Compound)
Mesalazine (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Kanamycin (Compound) and Kanamycin (Compound) resembles Tobramycin (Compound)
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Tobramycin (Compound)
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin (Compound) resembles Tobramycin (Compound)
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin (Compound) resembles Tobramycin (Compound)
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal (Compound) causes Tubulointerstitial nephritis (Side Effect) and Tubulointerstitial nephritis (Side Effect) is caused by Tobramycin (Compound)
Mesalazine (Compound) resembles Salicylate-sodium (Compound) and Salicylate-sodium (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Tobramycin (Compound)